Business

Medical diagnostics company signs distribution contract for Covid-19 tests



Medical diagnostics company Omega has signed a three-year contract with testing company Screen4 to provide a testing service for Covid-19.

The testing service, based at Omega’s in-house laboratory in Littleport in Cambridgeshire, will use its Mologic ELISA antibody test for the virus.

Enzyme Linked Immuno-Sorbent Assay (ELISA) tests are one of the most proven laboratory technologies, used by the global diagnostics industry and for rapid tests including those Covid-19.

This distribution contract follows the launch of the AIM-listed, Alva-headquartered company’s antibody testing service announced on 26 January.

Screen4, based at Cirencester in Gloucestershire, has become a leading provider of Covid-19 testing services to the aviation, petrochemical, occupational health and consumer markets in the UK and across the Middle East and Far East.

Screen4 is also an approved provider under the UK Government general testing and ‘Test to Release’ Scheme.

Omega chief executive Colin King said: “Following on from setting up and launching our in-house testing service that utilises the Mologic COVID-19 IgG ELISA, I am pleased to be working with Screen4 as our first customer.

“Screen4 provide a synergistic approach involving health assessment and patient support to their clients.”

Screen4 managing director David Grouse said: “Omega are at the forefront in the development of vital testing technologies to help fight the Covid-19 virus.

“We will be supporting them through the distribution of their latest product – the COVID-19 ELISA Antibody testing service.

“The simple, usable nature of this product, particularly with regards to a properly CE marked self-collection sample kit for home use, is a major step forward in helping people understand their current status with regards to the virus.”

READ  Fraudsters target those who are self-isolating 

Don’t miss the latest headlines with our twice-daily newsletter – sign up here for free.



READ SOURCE

Leave a Reply

This website uses cookies. By continuing to use this site, you accept our use of cookies.